⚕ Clinician Reference · KDIGO 2020 Aligned · Hemodialysis · Prescribing Tool

Dialysate Sodium Balance Calculator Time-Averaged Na & Salt-Loading Risk

Hemodialysis prescribing tool that pairs the dialysate sodium profile (linear descending, three-tier step, or ascending–descending) with the pre-HD plasma sodium anchor to estimate net diffusive Na flux. A time-averaged dialysate Na (TAD-Na) more than ~1 mEq/L above the patient's pre-HD plasma Na pushes salt into the patient — driving interdialytic thirst, weight gain, and hypertension; matching TAD-Na to the plasma anchor delivers net-zero diffusive Na (the iso-natric prescription). Use alongside ultrafiltration profiling for tolerance without sodium loading.

Published: References: 4 Specialty: Nephrology · Hemodialysis Last Reviewed: Read time:

← All calculators & tools  ·  Iso-UF & Na/UF ramping guide →

Instructions
  1. Enter the pre-HD plasma sodium (mEq/L) — the patient's anchor value. Net diffusive Na flux is referenced to this number.
  2. Enter the start and end dialysate Na (mEq/L) — typical ranges 148–152 (start) and 136–138 (end) for a descending ramp. For an iso-natric prescription, set start = end = pre-HD plasma Na.
  3. Enter the session duration (min) and select the profile shape (linear descending, three-tier step, or ascending–descending).
  4. The time-averaged dialysate Na (TAD-Na), the plasma–TAD delta, and the salt-loading classification update automatically once all fields are valid.

All computation runs in your browser; no values are stored or transmitted.

When to Use

Use this tool when prescribing or troubleshooting a hemodialysis sodium profile — particularly for patients with interdialytic weight gain, refractory hypertension, intradialytic thirst, or planned sodium/UF ramping. The classification estimates whether the chosen dialysate Na profile pushes salt into the patient (positive diffusive Na flux) or extracts it (net-negative). Pair the result with the iso-UF & Na/UF ramping guide.

Appropriate population

Maintenance hemodialysis patients on a fixed or profiled dialysate Na. Especially useful when reviewing prescriptions in patients with high interdialytic weight gain (>3% of dry weight), poorly controlled volume-dependent hypertension, or persistent intradialytic thirst and cramping despite acceptable UF rate.

⚠️

When NOT to rely on it

This is a steady-state diffusive-flux estimate that ignores convective Na losses with UF, residual kidney function, and intradialytic plasma-Na changes from osmolar shifts. Do not use it to justify a high dialysate Na in patients with the osmolar-collapse phenotype (frequent symptomatic intradialytic hypotension with documented plasma osmolarity drop) — those decisions belong with the prescribing nephrologist after a complete osmolar review.

Pearls & Pitfalls
💡

The plasma anchor is the rule

Net diffusive Na flux is governed by the gradient between time-averaged dialysate Na and the patient's pre-HD plasma Na. A TAD-Na within ±1 mEq/L of the plasma anchor delivers a near-zero net diffusive load (the iso-natric target). A delta of +2 to +3 already constitutes mild salt loading; >+3 reliably increases interdialytic thirst, weight gain, and predialysis BP.

🔬

Profile shape changes the average, not just the peak

A linear 148→138 ramp and a flat 143 prescription deliver the same TAD-Na (143) — but the ramp may protect intradialytic stability via an initial osmolar buffer. A three-tier step from 150→144→138 (equal-time tiers) averages to ~144. An ascending–descending (A/D) profile usually averages between its peak and trough. Match TAD-Na to plasma, not just the start or end value.

🚫

Pitfalls

(1) Reading the start dialysate Na in isolation — a 152 start with a 136 end still averages to 144. (2) Using a high (>155) start dialysate Na as routine practice — this drives chronic salt loading in most patients and should be reserved for the documented osmolar-collapse phenotype. (3) Ignoring convective Na losses with UF (the diffusive estimate here is conservative for the typical clinical question of "is this prescription net-loading?"). (4) Treating a single pre-HD plasma Na as immutable — re-check across multiple sessions before re-prescribing the profile.

Why Use It

Dialysate sodium is one of the most under-appreciated dials in the hemodialysis prescription. A dialysate Na far above the patient's plasma anchor diffuses sodium into the patient over each session — the patient drinks more between sessions, gains more interdialytic fluid, raises blood pressure, and ultimately pays for the cumulative salt load with left-ventricular hypertrophy and worse cardiovascular outcomes. Conversely, an inappropriately low dialysate Na produces rapid plasma osmolar drops, intradialytic hypotension, and cramping. The iso-natric (plasma-anchored) prescription — TAD-Na within ±1 mEq/L of the pre-HD plasma Na — preserves intradialytic stability while keeping net diffusive Na flux near zero. This calculator makes the gradient explicit so you can audit, adjust, or document the prescription.

Dialysate Sodium Balance Calculator

Enter the pre-HD plasma Na, the start and end dialysate Na, the session duration, and select the profile shape. The time-averaged dialysate Na (TAD-Na), the plasma–TAD delta, and the salt-loading classification update live as you type.

The patient's anchor value. Net Na flux is referenced to this number.
Typical 148–152 for a descending ramp.
Typical 136–138 for a descending ramp.
Total prescribed dialysis time.
Determines how TAD-Na is computed from start & end.
Time-averaged dialysate Na
mEq/L
Plasma–TAD delta
TAD − plasma (mEq/L)
Net diffusive Na flux
interpretation
Profile flag: start dialysate Na > 155 mEq/L — avoid unless the osmolar-collapse phenotype is documented. Routine use drives chronic salt loading even when the end value is low.

⚕ Song JH et al. JASN 2005;16(1):237–246 · Oliver MJ et al. JASN 2001;12(1):151–156 · Sang GL et al. AJKD 1997;29(5):669–677 · Flythe JE et al. Kidney Int 2020;97(5):861–876. Diffusive estimate; ignores convective Na losses with UF and intradialytic plasma-osmolar shifts. The A/D average is approximated as (peak + trough)/2. For licensed clinicians; not a substitute for individualized assessment.

How to Interpret

The classification turns the plasma–TAD delta into a salt-loading verdict:

Plasma–TAD delta (mEq/L)ClassificationAction
|delta| ≤ 1Net-zero (safe)Iso-natric prescription. Keep as is. Cumulative diffusive Na flux is near zero.
1 < |delta| ≤ 3Mild salt loading (caution)Plausible driver of interdialytic weight gain and BP. Trend pre-HD plasma Na across sessions and consider lowering TAD-Na by 1–2 mEq/L (drop start or end of the ramp).
|delta| > 3Salt loading (STOP unless osmolar-collapse phenotype documented)Rework the profile toward the plasma anchor. The only routine exception is the documented osmolar-collapse phenotype (recurrent symptomatic intradialytic hypotension with measured plasma-osmolarity drop), where a small positive delta may be intentional.

Note: a negative delta of similar magnitude (TAD-Na < plasma) signals diffusive Na removal — typically well tolerated when small, but watch for plasma osmolarity drops, cramping, and intradialytic hypotension at larger negative deltas.

Next Steps

Use the salt-loading classification to guide the next prescription change.

  • Net-zero: retain the profile. Re-audit at the next pre-HD plasma Na drift > 2 mEq/L or any change in interdialytic weight gain.
  • Mild salt loading: drop the dialysate Na ramp by 1–2 mEq/L (typically lower the end value first), reassess interdialytic weight gain and pre-HD BP after 2–3 weeks.
  • Salt loading: rework the prescription toward the plasma anchor. Pair with UF profiling (see the iso-UF & Na/UF ramping guide) and reinforce dietary sodium restriction (see the sodium & salt reduction guide).
  • Document the rationale in the dialysis order. For the osmolar-collapse phenotype, record the documenting plasma-osmolarity drop and the planned re-audit interval.
Evidence & References

Profile averaging conventions

Profile shapeTAD-Na formula (this tool)Note
Linear descending(start + end) / 2Exact mean for a linear ramp over fixed time.
Step (3 equal-time tiers)Mean of (start, midpoint, end)Tiers held for equal thirds of session duration.
A/D (ascending–descending)(peak + trough) / 2Approximation — the true average depends on tier durations and ramp slopes.

Classification thresholds

Plasma–TAD deltaClassification
|delta| ≤ 1 mEq/LNet-zero (safe)
1 < |delta| ≤ 3 mEq/LMild salt loading (caution)
|delta| > 3 mEq/LSalt loading (STOP unless osmolar-collapse phenotype documented)

The ±1 mEq/L band approximates measurement uncertainty in plasma Na and the iso-natric target reported in the sodium-balance literature. Profile flag fires when start dialysate Na > 155 mEq/L.

References

  1. Song JH, Lee SW, Suh CK, Kim MJ. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. J Am Soc Nephrol. 2005;16(1):237–246. PMID: 15563561.
  2. Oliver MJ, Edwards LJ, Churchill DN. Impact of sodium and ultrafiltration profiling on hemodialysis-related symptoms. J Am Soc Nephrol. 2001;12(1):151–156. PMID: 11134261.
  3. Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM. Sodium ramping in hemodialysis: a study of beneficial and adverse effects. Am J Kidney Dis. 1997;29(5):669–677. PMID: 9159299.
  4. Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: Conclusions from a KDIGO Controversies Conference. Kidney Int. 2020;97(5):861–876. PMID: 32278617.
Important: This calculator is an educational aid for licensed clinicians and does not replace individualized hemodialysis prescribing. It estimates time-averaged dialysate Na and net diffusive sodium flux relative to a pre-HD plasma anchor; it ignores convective Na losses with ultrafiltration, residual kidney function, and intradialytic plasma-osmolarity shifts. The A/D average is an approximation. Any change to dialysate Na should integrate volume status, BP control, intradialytic symptoms, and current institutional protocols.
References 4 sources
  1. Song JH et al. JASN. 2005;16(1):237–246 (PMID: 15563561)
  2. Oliver MJ et al. JASN. 2001;12(1):151–156 (PMID: 11134261)
  3. Sang GL et al. Am J Kidney Dis. 1997;29(5):669–677 (PMID: 9159299)
  4. Flythe JE et al. Kidney Int. 2020;97(5):861–876 (PMID: 32278617)
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides